Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Andre De Souza; Fabio A. Tavora; Devalingam Mahalingam; Pamela N. Munster; Howard P. Safran; Wafik S. El-Deiry; Benedito A. Carneiro

doi:10.3389/fimmu.2020.595289

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Andre De Souza, Fabio A. Tavora, Devalingam Mahalingam, Pamela N. Munster, Howard P. Safran, Wafik S. El-Deiry, Benedito A. Carneiro

Mays Cancer Center

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Article number	595289
Journal	Frontiers in immunology
Volume	11
DOIs	https://doi.org/10.3389/fimmu.2020.595289
State	Published - Oct 19 2020

Keywords

9-ING-41
COVID
COVID-19
GSK-3 inhibitor
GSK-3b inhibitor
SARS-CoV21
glycogen synthase kinase-3 (GSK-3) inhibitor
glycogen synthase kinase-3 (GSK3)

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.3389/fimmu.2020.595289

Cite this

Commentary : GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. / De Souza, Andre; Tavora, Fabio A.; Mahalingam, Devalingam; Munster, Pamela N.; Safran, Howard P.; El-Deiry, Wafik S.; Carneiro, Benedito A.

In: Frontiers in immunology, Vol. 11, 595289, 19.10.2020.

Research output: Contribution to journal › Comment/debate › peer-review

@article{a9f5e1077bb946a69e83db4ffadb6964,

title = "Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response",

keywords = "9-ING-41, COVID, COVID-19, GSK-3 inhibitor, GSK-3b inhibitor, SARS-CoV21, glycogen synthase kinase-3 (GSK-3) inhibitor, glycogen synthase kinase-3 (GSK3)",

author = "{De Souza}, Andre and Tavora, {Fabio A.} and Devalingam Mahalingam and Munster, {Pamela N.} and Safran, {Howard P.} and El-Deiry, {Wafik S.} and Carneiro, {Benedito A.}",

year = "2020",

month = oct,

day = "19",

doi = "10.3389/fimmu.2020.595289",

language = "English (US)",

volume = "11",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Commentary

T2 - GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

AU - De Souza, Andre

AU - Tavora, Fabio A.

AU - Mahalingam, Devalingam

AU - Munster, Pamela N.

AU - Safran, Howard P.

AU - El-Deiry, Wafik S.

AU - Carneiro, Benedito A.

PY - 2020/10/19

Y1 - 2020/10/19

KW - 9-ING-41

KW - COVID

KW - COVID-19

KW - GSK-3 inhibitor

KW - GSK-3b inhibitor

KW - SARS-CoV21

KW - glycogen synthase kinase-3 (GSK-3) inhibitor

KW - glycogen synthase kinase-3 (GSK3)

UR - http://www.scopus.com/inward/record.url?scp=85094886442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094886442&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2020.595289

DO - 10.3389/fimmu.2020.595289

M3 - Comment/debate

C2 - 33193448

AN - SCOPUS:85094886442

VL - 11

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 595289

ER -